Management of patients with hidradenitis suppurativa during the COVID‐19 pandemic: Risk and benefit of immunomodulatory therapy

Molinelli, Elisa; Diotallevi, Federico; Simonetti, Oriana; Brisigotti, Valerio; Sapigni, Claudia; Radi, Giulia; Campanati, Anna; Offidani, Annamaria

doi:10.1111/dth.14256

Cited by 8 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of COVID‐19 among cohorts of patients with inflammatory bowel disease 16 and psoriasis 17 under treatment with biologicals was very limited, and the same held true for the two reported cohorts of patients with HS under treatment with adalimumab 12,18 (Table 1). Furthermore, it needs to be considered that biological modifiers used in HS therapy, such as anakinra, are proposed for the management of COVID‐19 patients 19 .…”

Section: Covid‐19 and Hsmentioning

confidence: 70%

Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

Giamarellos‐Bourboulis

Bettoli

Jemec

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

The reported incidence of COVID‐19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID‐19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID‐19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti‐COVID‐19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS‐CoV2 and patients affected by metabolic syndrome constitute a high‐risk group for COVID‐19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non‐living virus anti‐SARS‐CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.

show abstract

Section: Covid‐19 and Hsmentioning

confidence: 70%

Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

Giamarellos‐Bourboulis

Bettoli

Jemec

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…However, the role of biologic treatment during infection with COVID‐19 remains controversial. 16 , 17 Given the uncertainty and fear of HS patients concerning risks of infection with COVID‐19 under HS treatment, close patient follow‐up and counselling are crucial. Telemedicine may be a useful and practicable option, in order to minimise the risk of SARS‐CoV‐2 infection of vulnerable HS patients, maintain physician contact to HS patients, and thus, maintain optimal management of HS patients.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, biologic treatment with adalimumab may expose HS patients to an additional risk for severe infection. However, the role of biologic treatment during infection with COVID‐19 remains controversial 16,17 . Given the uncertainty and fear of HS patients concerning risks of infection with COVID‐19 under HS treatment, close patient follow‐up and counselling are crucial.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID‐19 pandemic on patients with hidradenitis suppurativa

Fiocco

Schlager

Kendziora

et al. 2022

International Wound Journal

View full text Add to dashboard Cite

The COVID‐19 pandemic caused collateral damage to patients with acute and chronic conditions. In this mono‐centre cross‐sectional study, we sought to evaluate the impact of the COVID‐19 pandemic on patients with hidradenitis suppurativa (HS). In June 2020, we sent an anonymous survey to 109 patients, who were diagnosed with HS in our outpatient clinic from May 2018 to April 2020. Fifty patients (45.9%) completed and returned the survey. Forty‐five participants (90.0%) denied any cancellation of hospitalisation due to the COVID‐19 pandemic. Hospitalisation was postponed in 8% of cases and cancelled in 2%. Compared to prior to the pandemic, fewer patients consulted their primary physician for changing wound dressings and more changed the dressings themselves or were assisted by their family members. 13% of patients avoided doctor visits due to fear of COVID‐19 and 26.1% minimised doctor visits. The Dermatology Life Quality Index showed a moderate to very severe impact on patients' Quality of Life (mean score = 10.06). Only one patient used telemedicine. Due to limited access to primary care and fear of COVID‐19, the pandemic had a detectable impact on the hospital management of patients with HS in our facility. Telemedicine still plays a negligible role in primary wound care.

show abstract

“…Only one patient reported COVID-19 related symptoms which subsided immediately and three patients (one under rifampicin+clindamycin treatment, the two others under adalimumab treatment) had been isolated due to a close contact to someone with a suspected diagnosis of COVID-19, without having positive real-time PCR test result [20]. Furthermore, Molinelli et al [21] declared that none of the 35 patients treated with adalimumab for HS in their cohort group had any symptoms related to COVID-19 and the ongoing biologic treatment was not discontinued in any patient. Supporting the findings of this study, we also did not find any statistically significant difference between the presence of COVID-19 symptoms and the given treatment modalities when categorized as oral antibiotics± topical antibiotics, oral retinoid, TNF-α inhibitors ± oral/topical antibiotics and topical antibiotics (P = 0.124).…”

Section: Discussionmentioning

confidence: 99%

Impact of Covid-19 Pandemic on Hidradenitis Suppurativa Patients: a Cross-Sectional Study From Tertiary Referral Hospital

Bostan

Jarbou

Karaduman

et al. 2022

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) is a chronic, disabling skin disorder which is characterized by recurrent attacks of nodule, abscess, sinus tract formation which eventually leads to significant scarring. Oral/topical antibiotics, oral retinoids and TNF-alpha inhibitors are used to control disease activity and improve symptoms. Objective: In the present study, we aimed to determine the prevalance of COVID-19 real-time polymerase chain reaction (RT-PCR) positivity and Covid-19 related symptoms in relation to the age, gender, body mass index (BMI), disease duration, accompanying systemic diseases, treatment used for HS, treatment duration and smoking. Methods: We conducted a comparative, cross-sectional study of 178 patients diagnosed with HS in a referral hospital. Age, gender, smoking status, BMI, treatment modalities used for HS, the presence of COVID-19 related symptoms, history of close contact to a person with COVID-19 and COVID-19 RT-PCR results were determined by a telephone questionnaire and checked from medical data records. Results: Sixty-three patients were female, whereas 115 patients were male. During Covid-19 pandemic, 94 out of 178 patients had Covid-19 related symptoms; Covid-19 RT-PCR test was performed in 109 (61.2%) patients. Thirty (27.5%) cases tested positive for Covid-19 whereas 79 (72.5%) tested negative. Conclusions: Patients having Covid-19 related symptoms were shown to have statistically significantly higher mean age compared to the ones who did not have any symptoms (p=0.031). No statistically significant relationship was found Covid-19 RT-PCR positivity and the type of treatment administered for HS when categorized as TNF-alpha inhibitor, oral retinoid, topical antibiotic and oral antibiotic group (p>0.05).

show abstract

Management of patients with hidradenitis suppurativa during the COVID‐19 pandemic: Risk and benefit of immunomodulatory therapy

Cited by 8 publications

References 11 publications

Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

Impact of the COVID‐19 pandemic on patients with hidradenitis suppurativa

Impact of Covid-19 Pandemic on Hidradenitis Suppurativa Patients: a Cross-Sectional Study From Tertiary Referral Hospital

Contact Info

Product

Resources

About